keyword
https://read.qxmd.com/read/38569855/-safety-and-efficacy-of-7-day-administration-of-azacitidine-and-venetoclax-combination-therapy-7-7-therapy
#21
JOURNAL ARTICLE
Yuki Osada, Hikari Kanai-Sudo, Taro Mizuki, Sakae Tanosaki, Ken Suzuki
Acute myelogenous leukemia (AML) has a poor prognosis in patients who are ineligible for intensive chemotherapy. The combination of azacitidine and venetoclax has been shown to have high overall efficiency and remission rates, even in patients ineligible for aggressive chemotherapy. However, myelosuppression is often prolonged after treatment, and infection can also occur. Severe myelosuppression is often addressed by dose titration, but specific dose titration methods have not been clarified. We used the standard induction therapy with azacitidine plus venetoclax, and if blasts decreased to 20% or less, switched to 7+7 therapy to shorten venetoclax to 7 days starting from the next cycle...
2024: [Rinshō Ketsueki] the Japanese Journal of Clinical Hematology
https://read.qxmd.com/read/38564277/post-marketing-safety-concerns-with-palbociclib-a-disproportionality-analysis-of-the-fda-adverse-event-reporting-system
#22
JOURNAL ARTICLE
Minghui Sun, Qian Cheng, Xuan Shi, Yazheng Zhao, Shupeng Zou
OBJECTIVES: To explore the association between palbociclib and related adverse events (AEs) in the real world through U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) database. METHODS: The signal strength of palbociclib-related AEs was done by disproportionality analysis. Clinical priority of palbociclib-related AEs was scored and ranked by assessing five different features. Serious and non-serious cases were compared by Mann-Whitney U test or Chisquared (χ2 ) test...
April 2, 2024: Expert Opinion on Drug Safety
https://read.qxmd.com/read/38555858/computational-identification-of-potential-modulators-of-heme-regulated-inhibitor-hri-for-pharmacological-intervention-against-sickle-cell-disease
#23
JOURNAL ARTICLE
Afolabi J Owoloye, Samuel O Olubode, Adewale Ogunleye, Emmanuel T Idowu, Kolapo M Oyebola
Sickle cell disease (SCD) poses a significant health challenge and therapeutic approaches often target fetal hemoglobin (HbF) to ameliorate symptoms. Hydroxyurea, a current therapeutic option for SCD, has shown efficacy in increasing HbF levels. However, concerns about myelosuppression and thrombocytopenia necessitate the exploration of alternative compounds. Heme-regulated inhibitor (HRI) presents a promising target for pharmacological intervention in SCD due to its association with HbF modulation. This study screened compounds for their potential inhibitory functions against HRI...
March 31, 2024: Journal of Biomolecular Structure & Dynamics
https://read.qxmd.com/read/38545201/probiotic-derived-ferrichrome-induces-ddit3-mediated-antitumor-effects-in-esophageal-cancer-cells
#24
JOURNAL ARTICLE
Takehito Kunogi, Hiroaki Konishi, Aki Sakatani, Kentaro Moriichi, Chikage Yamamura, Koji Yamamoto, Shin Kashima, Katsuyoshi Ando, Nobuhiro Ueno, Hiroki Tanaka, Toshikatsu Okumura, Mikihiro Fujiya
Esophageal cancer, which is common among the elderly, has the poorest prognosis among gastrointestinal cancers. Previously, we demonstrated that ferrichrome, produced by the probiotic Lactobacillus casei , exhibited anti-tumor effects in various gastrointestinal cancers, including colorectal and gastric cancers, with minimal effects on non-cancerous intestinal cells. However, it remains unclear whether ferrichrome exerts anti-tumor effects in esophageal cancer. A sulforhodamine B assay revealed that ferrichrome suppressed esophageal adenocarcinoma (OE33, OE19) and squamous cell carcinoma (KYSE70) cells...
March 30, 2024: Heliyon
https://read.qxmd.com/read/38541608/anticancer-potential-of-pyridoxine-based-doxorubicin-derivatives-an-in-vitro-study
#25
JOURNAL ARTICLE
Rawdah Karwt, Oksana V Bondar, Mikhail V Pugachev, Tharaa Mohammad, Aisylu S Kadyrova, Roman S Pavelyev, Saleh Alrhmoun, Oleg I Gnezdilov, Yurii G Shtyrlin
Doxorubicin (DOX) is a prevalent anticancer agent; however, it is unfortunately characterized by high cardiotoxicity, myelosuppression, and multiple other side effects. To overcome DOX limitations, two novel pyridoxine-derived doxorubicin derivatives were synthesized (DOX-1 and DOX-2). In the present study, their antitumor activity and mechanism of action were investigated. Of these two compounds, DOX-2, in which the pyridoxine fragment is attached to the doxorubicin molecule via a C3 linker, revealed higher selectivity against specific cancer cell types compared to doxorubicin and a promising safety profile for conditionally normal cells...
February 20, 2024: Life
https://read.qxmd.com/read/38517014/traditional-chinese-medicine-for-gastric-cancer-an-evidence-mapping
#26
JOURNAL ARTICLE
Zelei Dai, Chenfeng Tan, Jun Wang, Qin Wang, Ying Wang, Ying He, Yalan Peng, Mingyou Gao, Yonggang Zhang, Lei Liu, Ningying Song, Nian Li
As a complementary and alternative therapy, traditional Chinese medicine (TCM) has been playing a significant role in gastric cancer treatment. Data from individual systematic reviews have not been comprehensively summarized, and the relationship between certain interventions and outcomes are ill-defined. This study aimed to analyze the advantages of TCM interventions for gastric cancer by the method of evidence mapping. We searched PubMed, Embase, Web of Science, China National Knowledge Infrastructure, Chinese Scientific Journals Database, and Wanfang Database for systematic reviews of TCM treating gastric cancer up to December 31, 2023...
March 22, 2024: Phytotherapy Research: PTR
https://read.qxmd.com/read/38516379/efficacy-and-safety-of-different-chemotherapy-regimens-combined-with-thalidomide-in-the-treatment-of-diagnosed-hiv-associated-diffuse-large-b-cell-lymphoma
#27
REVIEW
Peng Fei Tao, Chuan Qian, Qi Wen Zhou, Sen Lin, Dan Qing Wang, Xi Wang, Shi Fen Chen, Hai Yan Min
OBJECTIVE: To investigate the short-term efficacy and safety of different chemotherapy regimens combined with thalidomide, in the treatment of low-income patients with newly diagnosed HIV-associated diffuse large B-cell lymphoma. METHODS: A retrospective analysis was performed on 42 patients with HIV-DLBCL who were admitted to the Infectious Diseases Department of Yunnan Provincial Infectious Diseases Hospital from January 2018 to December 2020. 14 cases (including 1 case in stage II and 13 cases in stage III/IV) were treated with R-CHOP, 24 cases (including 1 case in stage II and 23 cases in stage III/IV) were treated with R-DAEPOCH, and 4 cases (including 1 case in stage II and 3 cases in stage III/IV) were treated with EPOCH...
2024: Leukemia Research Reports
https://read.qxmd.com/read/38511127/ruxolitinib-iv-immunoglobulin-and-high-dose-glucocorticoids-for-critically-ill-adults-with-secondary-hemophagocytic-lymphohistiocytosis-a-single-center-observational-pilot-study
#28
JOURNAL ARTICLE
Laura Scholz, Florian Posch, Eduard Schulz, Max Gornicec, Albert Wölfler, Alexander C Reisinger, Andreas Reinisch, Philipp Eller, Florian Eisner, Philipp Kreuzer, Martin Stradner, Alexander R Rosenkranz, Florian Krammer, Gernot Schilcher, Robert Krause, Stefan Hatzl
OBJECTIVES: Secondary hemophagocytic lymphohistiocytosis (sHLH) is a cytokine-driven inflammatory syndrome that is associated with substantial morbidity and mortality and frequently leads to ICU admission. Overall survival in adults with sHLH remains poor, especially in those requiring intensive care. Classical chemotherapeutic treatment exhibits myelosuppression and toxicity. Recently, inhibition of Janus kinase signaling by ruxolitinib has shown efficacy in pediatric HLH. We therefore aimed to determine the activity and safety of a ruxolitinib-based regimen, in critically ill adults with sHLH...
February 2024: Critical care explorations
https://read.qxmd.com/read/38501267/risk-factors-associated-with-high-dose-methotrexate-induced-toxicities
#29
REVIEW
Wenshu Li, Jiayi Mo, Zhilin Yang, Zhigang Zhao, Shenghui Mei
INTRODUCTION: High-dose methotrexate (HDMTX) therapy poses challenges in various neoplasms due to individualized pharmacokinetics and associated adverse effects. Our purpose is to identify early risk factors associated with HDMTX-induced toxicities, paving the way for personalized treatment. AREAS COVERED: A systematic review of PubMed and Cochrane databases was conducted for articles from inception to July 2023. Eligible studies included reviews, clinical trials, and real-world analyses...
March 19, 2024: Expert Opinion on Drug Metabolism & Toxicology
https://read.qxmd.com/read/38496907/final-report-of-the-phase-ii-next-cns-gct-4-trial-gempox-followed-by-marrow-ablative-chemotherapy-for-recurrent-intracranial-germ-cell-tumors
#30
JOURNAL ARTICLE
Margaret Shatara, Megan Blue, Joseph Stanek, Yin A Liu, Daniel M Prevedello, Pierre Giglio, Vinay K Puduvalli, Sharon L Gardner, Jeffrey C Allen, Kenneth K Wong, Marvin D Nelson, Floyd H Gilles, Roberta H Adams, Jasmine Pauly, Katrina O'Halloran, Ashley S Margol, Girish Dhall, Jonathan L Finlay
BACKGROUND: Patients with relapsed intracranial germinoma can achieve durable remission with standard chemotherapy regimens and/or reirradiation; however, innovative therapies are required for patients with relapsed and/or refractory intracranial nongerminomatous germ cell tumors (NGGCTs) due to their poor prognosis. Improved outcomes have been reported using reinduction chemotherapy to achieve minimal residual disease, followed by marrow-ablative chemotherapy (HDCx) with autologous hematopoietic progenitor cell rescue (AuHPCR)...
April 2024: Neuro-oncology Practice
https://read.qxmd.com/read/38494684/a-randomized-trial-of-bacteroides-fragilis-839-on-preventing-chemotherapy-induced-myelosuppression-and-gastrointestinal-adverse-effects-in-breast-cancer-patients
#31
RANDOMIZED CONTROLLED TRIAL
Ting Zeng, Yu-Hong Deng, Chu-Hui Lin, Xin-Xin Chen, Hai-Xia Jia, Xiao-Wu Hu, Ting Xia, Yun Ling, Le-Hong Zhang, Teng-Fei Cao
BACKGROUND AND OBJECTIVES: To evaluate the potential benefits of Bacteroides fragilis 839 (BF839), a next-generation probiotics, in reducing myelosuppression and gastrointestinal toxicity associated with chemotherapy in breast cancer patient. METHODS AND STUDY DESIGN: 40 women with early breast cancer were randomly assigned to the BF839 (n=20) or placebo (n=20) during the administration of adjuvant chemotherapy (4 cycles of epirubicin 100mg/m2 and cyclophosphamide 600mg/m2)...
March 2024: Asia Pacific Journal of Clinical Nutrition
https://read.qxmd.com/read/38491305/differential-in-vivo-roles-of-mpl-cytoplasmic-tyrosine-residues-in-murine-hematopoiesis-and-myeloproliferative-disease
#32
JOURNAL ARTICLE
Kira Behrens, Maria Kauppi, Elizabeth M Viney, Andrew J Kueh, Craig D Hyland, Tracy A Willson, Liam Salleh, Carolyn A de Graaf, Jeffrey J Babon, Marco J Herold, Nicos A Nicola, Warren S Alexander
Thrombopoietin (Tpo), which binds to its specific receptor, the Mpl protein, is the major cytokine regulator of megakaryopoiesis and circulating platelet number. Tpo binding to Mpl triggers activation of Janus kinase 2 (Jak2) and phosphorylation of the receptor, as well as activation of several intracellular signalling cascades that mediate cellular responses. Three tyrosine (Y) residues in the C-terminal region of the Mpl intracellular domain have been implicated as sites of phosphorylation required for regulation of major Tpo-stimulated signalling pathways: Mpl-Y565, Mpl-Y599 and Mpl-Y604...
March 15, 2024: Leukemia
https://read.qxmd.com/read/38484953/adjuvant-treatment-with-cordyceps-sinensis-for-lung-cancer-a-systematic-review-and-meta-analysis-of-randomized-controlled-trials
#33
REVIEW
Canran Wang, Jiawei Wang, Yuanfu Qi
ETHNOPHARMACOLOGICAL RELEVANCE: Cordyceps sinensis (CS) is a fungus parasitic on lepidopteran larvae which is often used to treat lung diseases and regulate immune function. AIM OF THE STUDY: This review aimed to evaluate the efficacy of CS in the adjuvant treatment of lung cancer. MATERIALS AND METHODS: As of June 2022, the electronic database search was conducted in PubMed, EMBASE, Cochrane Library, China Biomedical Literature Database (CBM), China National Knowledge Infrastructure (CNKI), Wanfang Database and China Science Journal Database (VIP database)...
June 12, 2024: Journal of Ethnopharmacology
https://read.qxmd.com/read/38484357/association-of-clinical-factors-with-thrombocytopenia-in-patients-receiving-linezolid-treatment-a-retrospective-study
#34
JOURNAL ARTICLE
Le Thi Phuong Thao, Nguyen Duc Trung, Le Thi My, Le Minh Hong, Bui Viet Hoan, Vu Quang Hung, Pham Dang Hai
INTRODUCTION: Linezolid (LZD) plays an important role in the treatment of severe infections caused by Gram-positive bacteria. Thrombocytopenia is regarded as one of the most common side effects of linezolid, which results from the destruction of platelets or myelosuppression. The study aimed to identify the risk factors associated with the development of thrombocytopenia in Vietnamese patients. METHODOLOGY: This retrospective, descriptive cross-sectional study was performed on adult patients who received parenteral LZD therapy (1,200 mg/day) in at least 3 days between January 2020 and June 2021 at a tertiary referral hospital in Vietnam...
February 29, 2024: Journal of Infection in Developing Countries
https://read.qxmd.com/read/38484344/mortality-in-patients-with-hematological-malignancies-febrile-neutropenia-and-septic-shock
#35
JOURNAL ARTICLE
Beda Islas-Muñoz, Patricia Volkow-Fernández, Jorge Silva-Zamora, Ana Ramírez-Ibarguen, Patricia Cornejo-Juárez
INTRODUCTION: Patients with severe neutropenia who develop septic shock (SS) have high mortality. This study aimed to evaluate the risk factors and mortality of SS in patients with HM and febrile neutropenia. METHODOLOGY: We included all patients with hematological malignancies (HM) who presented fever and severe neutropenia, admitted to an oncological tertiary care center in Mexico City for one year. RESULTS: Two hundred ninety-two episodes of fever and severe neutropenia were documented; 68 patients (23...
February 29, 2024: Journal of Infection in Developing Countries
https://read.qxmd.com/read/38477559/mesenchymal-stem-cells-involved-strategies-for-rheumatoid-arthritis-therapy
#36
REVIEW
Chaoyang Li, Yifu Sun, Weiguo Xu, Fei Chang, Yinan Wang, Jianxun Ding
Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by chronic inflammation of the joints and bone destruction. Because of systemic administration and poor targeting, traditional anti-rheumatic drugs have unsatisfactory treatment efficacy and strong side effects, including myelosuppression, liver or kidney function damage, and malignant tumors. Consequently, mesenchymal stem cells (MSCs)-involved therapy is proposed for RA therapy as a benefit of their immunosuppressive and tissue-repairing effects...
March 13, 2024: Advanced Science (Weinheim, Baden-Wurttemberg, Germany)
https://read.qxmd.com/read/38462913/integration-of-network-pharmacology-and-experimental-validation-to-explore-jixueteng-yinyanghuo-herb-pair-alleviate-cisplatin-induced-myelosuppression
#37
JOURNAL ARTICLE
Yi Liu, Shuying Dai, Yixiao Xu, Yuying Xiang, Yao Zhang, Zeting Xu, Lin Sun, Gao-Chen-Xi Zhang, Qijin Shu
Jixueteng, the vine of the bush Spatholobus suberectus Dunn., is widely used to treat irregular menstruation and arthralgia. Yinyanghuo, the aboveground part of the plant Epimedium brevicornum Maxim., has the function of warming the kidney to invigorate yang. This research aimed to investigate the effects and mechanisms of the Jixueteng and Yinyanghuo herbal pair (JYHP) on cisplatin-induced myelosuppression in a mice model. Firstly, ultra-high performance liquid chromatography quadrupole time-of-flight mass spectrometry (UPLC-Q-TOF/MS) screened 15 effective compounds of JYHP decoction...
2024: Integrative Cancer Therapies
https://read.qxmd.com/read/38458424/pancytopenia-following-adjuvant-therapy-with-interferon-gamma-ifn-%C3%AE-in-a-patient-with-disseminated-nocardiosis
#38
Thomas Derungs, Denis Poddubnyy, Thomas Schneider
A patient with disseminated nocardiosis developed pancytopenia after treatment with recombinant interferon gamma (IFN-γ). While no prior clinical reports link pancytopenia to IFN-γ, our observations align with basic research on myelosuppressive effects of IFN-γ. Adjunctive IFN-γ may improve standard nocardiosis therapy, but vigilant monitoring of its hematological effects is necessary.
March 6, 2024: International Journal of Infectious Diseases: IJID
https://read.qxmd.com/read/38456691/a-real-world-pharmacovigilance-study-of-fda-adverse-event-reporting-system-faers-events-for-bruton-s-tyrosine-kinase-inhibitors-btkis-single-and-its-combination-therapy
#39
JOURNAL ARTICLE
Sichun Xiang, Rongbin Shen, Jingjing Xiang, Ni Zhu, Jianyou Gu, Jianping Shen, Yu Zhang, Hangping Ge
BACKGROUND: Bruton's tyrosine kinase inhibitors (BTKis) are targeted treatments for B-cell tumors but have significant side effects. This study assesses and contrasts the side effects of BTKis alone and its four combination therapies. RESEARCH DESIGN AND METHODS: The reporting odds ratio (ROR) was used to analyze the data on three BTKis monotherapies and combinations of ibrutinib with rituximab, obinutuzumab, venetoclax, and lenalidomide in the FDA Adverse Event Reporting System (FAERS) database up to December 2022...
March 18, 2024: Expert Opinion on Drug Safety
https://read.qxmd.com/read/38453980/the-deleterious-effects-of-sofosbuvir-and-ribavirin-antiviral-drugs-against-hepatitis-c-virus-on-different-body-systems-in-male-albino-rats-regarding-reproductive-hematological-biochemical-hepatic-and-renal-profiles-and-histopathological-changes
#40
JOURNAL ARTICLE
Rana A Ali, Eatemad A Awadalla, Yahia A Amin, Samer S Fouad, Maha Abd-El Baki Ahmed, Mohammed H Hassan, Emaad Abdel-Kahaar, Rehab H Abdel-Aziz
Sofosbuvir is one of the crucial drugs used in the treatment of chronic hepatitis C virus (HCV) in adults and children with compensated liver disease, including cirrhosis. It may be used alone or with other drugs. Ribavirin is an antiviral medication used to treat HCV infection. It is not effective when used alone and must be used in combination with other medications, such as sofosbuvir. This study pertains to a comprehensive assessment of the deleterious effects of sofosbuvir (an antiviral drug against chronic HCV) or sofosbuvir combined with ribavirin (an antiviral drug against RNA and DNA viruses) on several biological activities of the body, including hematological, hormonal, biochemical, histological, and immunohistochemical examinations during a long-standing period on male healthy rats...
March 7, 2024: Scientific Reports
keyword
keyword
97609
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.